ClinicalTrials.gg
CompletedNCT03112577Updated Jan 18, 2020

Study of REGN3500 and Dupilumab in Patients With Asthma

A Phase 1 interventional study of REGN3500 and Dupilumab in Asthma, Allergic, sponsored by Regeneron Pharmaceuticals. Completed at 5 sites in 2 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2020-01-18.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2019, 7 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing dupilumab in Asthma — 7 open to participants now, 12 under way, 2 of them phase 3. dupilumab · Asthma.

Enrollment
26th of 31
32 · median 120
Started
2017
with 1 other
Phase 1
Only one
of the 31
Registered
8th of 31
by date
Lead sponsor
3 of 31
Regeneron Pharmaceuticals

Among the 31 studies testing dupilumab in Asthma, this one is the 26th largest by enrollment, is one of 2 that started in 2017, is the only one in phase 1, and was the 8th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 31 studies testing dupilumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing dupilumab in Asthma, or all of them as a file.
02

Study summary

To assess the effects of REGN3500, dupilumab, and REGN3500 plus dupilumab, compared with placebo, on changes in inflammatory gene expression signatures in sputum induced after a bronchial allergen challenge (BAC) in adults with mild allergic asthma, at week 4 after treatment initiation compared with those at screening.

03

Conditions studied

  • Asthma, Allergic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

KEY Inclusion Criteria:

  1. Male or female aged between 18 and 60 years
  2. Has a {BMI) of 17 to 33 kg/m2 at pre-study screening
  3. Has a history of mild allergic asthma for at least 6 months
  4. Is a non-smoker or ex-smoker for at least 12 months

KEY Exclusion Criteria:

  1. Has a history of life-threatening asthma
  2. Has been hospitalized or has attended the emergency room for asthma in the 12 months prior to screening
  3. Has a history of severe allergies or history of an anaphylactic reaction
  4. Has a history of drug or alcohol abuse within a year prior to the screening visit

Note: other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    REGN3500

    REGN3500: masked and randomized dosing regimen per protocol (part 1 only)

    Drug: REGN3500

  • Experimental
    Dupilumab

    Dupilumab: masked and randomized dosing regimen per protocol (part 1 only)

    Drug: Dupilumab

  • Experimental
    REGN3500 plus dupilumab

    REGN3500 plus dupilumab: masked and randomized dosing regimen per protocol (part 1 only)

    Drug: REGN3500 · Drug: Dupilumab

  • Experimental
    Placebo

    Placebo: masked and randomized dosing regimen per protocol (part 1 only)

    Drug: Placebo

  • Active comparator
    Fluticasone propionate

    Fluticasone propionate: open label dosing regimen per protocol (part 2 only)

    Drug: Fluticasone propionate

Interventions

06

What researchers measure

Primary outcomes

  1. Difference in bronchial allergen challenge (BAC)-induced changes in sputum inflammatory markers in individuals treated with REGN3500, dupilumab and the combination of REGN3500 plus dupilumab or placebo

    Time frame: Screening (pre-treatment) to week 4 after treatment initiation

Secondary outcomes

  1. Incidence of Treatment Emergent Adverse Events (TEAEs)

    Time frame: Baseline to week 42

  2. Severity of TEAEs

    Time frame: Baseline to week 42

  3. Serum concentration-time profile of REGN3500

    Assessed by maximum plasma concentration \[Cmax\]

    Time frame: Baseline to week 42

  4. Serum concentration-time profile of REGN3500: Tmax (time at Cmax)

    Time frame: Baseline to week 42

  5. Serum concentration-time profile of REGN3500: AUClast (area under the curve to the last measurable concentration)

    Time frame: Baseline to week 42

  6. Immunogenicity of REGN3500 and dupilumab

    Assessed by measurement of anti-drug antibodies (ADAs)

    Time frame: Baseline to week 42

  7. Serum concentration of total IL-33 after single IV dose

    Time frame: Up to Week 42

  8. Difference in the BAC-induced changes in sputum inflammatory mRNA signature in individual patients treated with fluticasone

    Time frame: Screening (pre-treatment) to day 4 after treatment initiation

07

Study locations

5 sites
  • WCCT Global
    Cypress, California 90630, United States
  • Celerion
    Belfast, BT9 6AD, United Kingdom
  • Hammersmith Medicine Research
    London, NW10 7EW, United Kingdom
  • Respiratory Clinical Trials Ltd
    London, W1G 8HU, United Kingdom
  • The Medicines Evaluation Unit
    Manchester, M23 9QZ, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Mar 2019, 21 months.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 21 months is above that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2017
First posted
Apr 13, 2017
StartActual
Jun 15, 2017
Primary completionActual
Mar 20, 2019
CompletionActual
Dec 9, 2019
Last update
Jan 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03112577
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Apr 13, 2017
Start date
Jun 15, 2017
Primary completion
Mar 20, 2019
Completion
Dec 9, 2019
Last update
Jan 18, 2020

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Itepekimab · Dupilumab

Start the discussion